10月19日 - ** Abivax（ABVX.PA）股价下跌约3%， 此前一度下跌9.9%，随后跌幅收窄
**有交易员指出，竞争对手吉利德（Gilead） GILD.O 的药片在中期肠道疾病临床试验中取得成功
** 吉利德表示，其试验性每日一次口服药emvistegrast(link) 在缓解中度至重度溃疡性结肠炎（一种慢性肠道疾病）症状方面，比安慰剂使更多患者症状得到缓解
** Abivax公司的obefazimod于6月在晚期临床试验中达到了主要目标 (link)，该公司7月表示，仍按 计划将于年底前向美国食品药品监督管理局（FDA）提交新药申请
** 包括本交易日跌幅在内，该股今年以来累计下跌37%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.